<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s13{background-color:#f5f5f5;text-align:left;color:#428bca;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s6{background-color:#ffffff;text-align:left;color:#000000;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s0{border-right:1px SOLID transparent;background-color:#deeaf6;text-align:center;font-weight:bold;color:#000000;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s15{background-color:#ffffff;text-align:left;text-decoration:underline;color:#428bca;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s2{border-bottom:1px SOLID transparent;border-right:1px SOLID transparent;background-color:#deeaf6;text-align:center;font-weight:bold;color:#000000;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s5{background-color:#f5f5f5;text-align:left;text-decoration:underline;color:#428bca;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s7{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:8pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s8{border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s12{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:8pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s10{background-color:#ffffff;text-align:left;color:#000000;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s9{border-left: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s11{background-color:#ffffff;text-align:left;color:#000000;font-family:'Calibri',Arial;font-size:8pt;vertical-align:middle;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s14{background-color:#ffffff;text-align:center;color:#000000;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s1{border-bottom:1px SOLID transparent;border-right:1px SOLID transparent;background-color:#deeaf6;text-align:center;font-weight:bold;color:#000000;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s4{background-color:#f5f5f5;text-align:center;color:#000000;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s3{background-color:#deeaf6;text-align:center;font-weight:bold;color:#000000;font-family:'Calibri',Arial;font-size:9pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}</style><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header freezebar-vertical-handle"></th><th id="0C0" style="width:100px" class="column-headers-background">A</th><th id="0C1" style="width:263px" class="column-headers-background">B</th><th id="0C2" style="width:134px" class="column-headers-background">C</th><th id="0C3" style="width:95px" class="column-headers-background">D</th><th id="0C4" style="width:90px" class="column-headers-background">E</th><th id="0C5" style="width:79px" class="column-headers-background">F</th><th id="0C6" style="width:100px" class="column-headers-background">G</th><th id="0C7" style="width:100px" class="column-headers-background">H</th><th id="0C8" style="width:68px" class="column-headers-background">I</th><th id="0C9" style="width:152px" class="column-headers-background">J</th><th id="0C10" style="width:371px" class="column-headers-background">K</th><th id="0C11" style="width:100px" class="column-headers-background">L</th></tr></thead><tbody><tr style='height:20px;'><th id="0R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">1</div></th><td class="s0" dir="ltr">No.</td><td class="s1" dir="ltr">Article Link</td><td class="s2" dir="ltr">Article</td><td class="s3" dir="ltr">Study Type</td><td class="s1">This is evidence</td><td class="s1">Drug</td><td class="s1">Property</td><td class="s1">Value (drop down - for non-quantitative assertions)</td><td class="s1">Meets Inclusion Criteria?</td><td class="s1">If you entered &#39;No&#39; - explain why</td><td class="s2">The sentence(s) that state the main assertion</td><td class="s1">The sentence(s), table(s), and/or figure(s) that specify the results</td></tr><tr><th style="height:3px" class="freezebar-cell freezebar-horizontal-handle"></th><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td></tr><tr style='height:87px;'><th id="0R1" style="height: 87px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 87px;">2</div></th><td class="s4" dir="ltr">1</td><td class="s5" dir="ltr"><a target="_blank" href="http://localhost/dbmiannotator/PMC1884190.html">http://localhost/dbmiannotator/PMC1884190.html</a></td><td class="s6" dir="ltr">Cooper_2003_12534645</td><td class="s6" dir="ltr">clinical study</td><td class="s6" dir="ltr">Against</td><td class="s6" dir="ltr">ketoconazole</td><td class="s6" dir="ltr">interacts_with</td><td class="s6" dir="ltr">Rosuvastatin</td><td class="s6" dir="ltr">Yes</td><td class="s6"></td><td class="s7" dir="ltr">p 97 The geometric mean (gmean) plasma concentrations of<br> rosuvastatin over time were similar when rosuvastatin was coadministered with ketoconazole and placebo (Figure 1).</td><td class="s6" dir="ltr">Fig 1 and Table 1</td></tr><tr style='height:20px;'><th id="0R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">3</div></th><td class="s4" dir="ltr" rowspan="2">2</td><td class="s5" dir="ltr" rowspan="2"><a target="_blank" href="http://localhost/dbmiannotator/PMC3922121.html">http://localhost/dbmiannotator/PMC3922121.html</a></td><td class="s8 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 227px; left: -1px;">DeGorter_2013_23876492</div></td><td class="s9"></td><td class="s9" dir="ltr">For</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 76px; left: -1px;">Rosuvastatin</div></td><td class="s10" dir="ltr">substrate_of</td><td class="s10" dir="ltr">OATP1B1</td><td class="s6" dir="ltr">Needs to be evaluated</td><td class="s10" dir="ltr"></td><td class="s7" dir="ltr">Multiple linear regression analysis indicated that plasma rosuvastatinconcentration was higher in individuals with the reduced function hepatic uptake transporterallele SLCO1B1 c.521C (p &lt; 0.0001),</td><td class="s6" dir="ltr">Table 2</td></tr><tr style='height:20px;'><th id="0R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">4</div></th><td class="s8 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 227px; left: -1px;">DeGorter_2013_23876492</div></td><td class="s9"></td><td class="s9" dir="ltr">For</td><td class="s10" dir="ltr">Atorvastatin</td><td class="s10" dir="ltr">substrate_of</td><td class="s10" dir="ltr">OATP1B1</td><td class="s6" dir="ltr">Needs to be evaluated</td><td class="s10" dir="ltr"></td><td class="s7" dir="ltr">Multiple linear regression analysis indicated that plasma atorvastatin concentration washigher in individuals with the SLCO1B1 c.521C allele (p &lt; 0.05) but lower in those patientswith the SLCO1B1 c.388G allele (p &lt; 0.01).</td><td class="s6" dir="ltr">Table 2</td></tr><tr style='height:20px;'><th id="0R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">5</div></th><td class="s4" dir="ltr" rowspan="4">3</td><td class="s5" dir="ltr" rowspan="4"><a target="_blank" href="http://localhost/dbmiannotator/PMC90851.html">http://localhost/dbmiannotator/PMC90851.html</a></td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Hsyu_2001_11709322</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10" dir="ltr">Nelfinavir</td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Atorvastatin</td><td class="s10" dir="ltr">Yes</td><td class="s10" dir="ltr"></td><td class="s7" dir="ltr">Nelfinavir increased the steady-state area under the plasma concentra-tion-time curve during one dosing period (AUC) of atorvastatin 74% and the maximum concentration (Cmax) of atorvastatin 122% and increased the AUC of simvastatin 505% and the Cmax of simvastatin 517%. Neither atorvastatin nor simvastatin appeared to alter the pharmacokinetics of nelfinavir.</td><td class="s6" dir="ltr">Figures 1, 2<br> Table 1</td></tr><tr style='height:20px;'><th id="0R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">6</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Hsyu_2001_11709322</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10" dir="ltr">Nelfinavir</td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Simvastatin</td><td class="s10" dir="ltr">Yes</td><td class="s10" dir="ltr"></td><td class="s7" dir="ltr">Nelfinavir increased the steady-state area under the plasma concentra-tion-time curve during one dosing period (AUC) of atorvastatin 74% and the maximum concentration (Cmax) of atorvastatin 122% and increased the AUC of simvastatin 505% and the Cmax of simvastatin 517%. Neither atorvastatin nor simvastatin appeared to alter the pharmacokinetics of nelfinavir.</td><td class="s6" dir="ltr">Figures 1, 2<br> Table 1</td></tr><tr style='height:20px;'><th id="0R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">7</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Hsyu_2001_11709322</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">Against</td><td class="s10" dir="ltr">Simvastatin</td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Nelfinavir</td><td class="s11" dir="ltr">No</td><td class="s7" dir="ltr">The study is not designed well enough to support assertions 3 and 4 (it used low dosages of atorvastatin and simvastatin plus they did not have true control data for nelfinavir plus they only measured AUC 0-12 hours. If AUC 0 -12 hours is positive then fine I can accept it as a surrogate for AUC 0 to infinity but I can not accept a negative based on AUC 0 -12 hours.</td><td class="s7" dir="ltr">Nelfinavir increased the steady-state area under the plasma concentra-tion-time curve during one dosing period (AUC) of atorvastatin 74% and the maximum concentration (Cmax) of atorvastatin 122% and increased the AUC of simvastatin 505% and the Cmax of simvastatin 517%. Neither atorvastatin nor simvastatin appeared to alter the pharmacokinetics of nelfinavir.</td><td class="s6" dir="ltr">Figures 1, 2<br> Table 1</td></tr><tr style='height:20px;'><th id="0R7" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">8</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Hsyu_2001_11709322</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">Against</td><td class="s10" dir="ltr">Atorvastatin</td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Nelfinavir</td><td class="s12" dir="ltr">No</td><td class="s7" dir="ltr">The study is not designed well enough to support assertions 3 and 4 (it used low dosages of atorvastatin and simvastatin plus they did not have true control data for nelfinavir plus they only measured AUC 0-12 hours. If AUC 0 -12 hours is positive then fine I can accept it as a surrogate for AUC 0 to infinity but I can not accept a negative based on AUC 0 -12 hours.</td><td class="s7" dir="ltr">Nelfinavir increased the steady-state area under the plasma concentra-tion-time curve during one dosing period (AUC) of atorvastatin 74% and the maximum concentration (Cmax) of atorvastatin 122% and increased the AUC of simvastatin 505% and the Cmax of simvastatin 517%. Neither atorvastatin nor simvastatin appeared to alter the pharmacokinetics of nelfinavir.</td><td class="s6" dir="ltr">Figures 1, 2<br> Table 1</td></tr><tr style='height:20px;'><th id="0R8" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">9</div></th><td class="s4" dir="ltr" rowspan="2">4</td><td class="s5" dir="ltr" rowspan="2"><a target="_blank" href="http://localhost/dbmiannotator/PMC3187007.html">http://localhost/dbmiannotator/PMC3187007.html</a></td><td class="s10" dir="ltr">Lee_2011_21825288</td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10" dir="ltr">Telaprevir</td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Amlodipine</td><td class="s10" dir="ltr">Yes</td><td class="s10"></td><td class="s7" dir="ltr">AUC of Amlodipine increased 2.79-fold when coadministered with Telaprevir</td><td class="s6" dir="ltr">Fig 1, Table 1</td></tr><tr style='height:20px;'><th id="0R9" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">10</div></th><td class="s10" dir="ltr">Lee_2011_21825288</td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10" dir="ltr">Telaprevir</td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Atorvastatin</td><td class="s10" dir="ltr">Yes</td><td class="s10"></td><td class="s7" dir="ltr">AUC of Atorvastatin increased 7.88 fold when coadministered with Telaprevir</td><td class="s6" dir="ltr">Fig 2, Table 1</td></tr><tr style='height:20px;'><th id="0R10" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">11</div></th><td class="s4" dir="ltr">5</td><td class="s5" dir="ltr"><a target="_blank" href="http://localhost/dbmiannotator/PMC3900249.html">http://localhost/dbmiannotator/PMC3900249.html</a></td><td class="s8 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 227px; left: -1px;">McDonald_2012_22398967</div></td><td class="s9"></td><td class="s9" dir="ltr">For</td><td class="s10" dir="ltr">Amiodarone</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 97px; left: -1px;">inhibition_constant</div></td><td class="s10" dir="ltr">CYP2C9</td><td class="s10" dir="ltr" colspan="2">Needs to be evaluated</td><td class="s7" dir="ltr">in vitro inhibition experiments were carried out with AMIO and its metabolites to measure the KI against CYP2C9-mediated (S)-warfarin 7-hydroxylation in HLM.</td><td class="s6" dir="ltr">Table 2, Fig 4</td></tr><tr style='height:20px;'><th id="0R11" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">12</div></th><td class="s4" dir="ltr" rowspan="6">6</td><td class="s5" dir="ltr" rowspan="6"><a target="_blank" href="http://localhost/dbmiannotator/PMC3769672.html">http://localhost/dbmiannotator/PMC3769672.html</a></td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Mueck_2013_23305158</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">Against</td><td class="s10" dir="ltr">Rivaroxaban</td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Midazolam</td><td class="s10" dir="ltr">Yes</td><td class="s10"></td><td class="s7" dir="ltr">Co-administration with midazolam led to an increase in rivaroxaban median tmax from 1.5 h to 4.0 h and slightly decreased the rivaroxaban mean Cmax by 12% compared with rivaroxaban alone, a change that was not statistically significant (90% CI-28%, 7%).Rivaroxaban mean AUC remained almost unchanged.</td><td class="s6" dir="ltr">Tables 1 and 2; Figure 1</td></tr><tr style='height:20px;'><th id="0R12" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">13</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Mueck_2013_23305158</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 76px; left: -1px;">ketoconazole</div></td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Rivaroxaban</td><td class="s10" dir="ltr">Yes</td><td class="s10"></td><td class="s7" dir="ltr">Co-administration with steady-state ketoconazole significantly increased the plasma concentrations of a single dose of rivaroxaban 10 mg compared with rivaroxaban alone. The mean AUC increased by 82% (90% CI 59%, 108%) and the mean Cmax increased by 53%(90% CI 27%, 85%)</td><td class="s6" dir="ltr">Tables 1 and 2; Figure 1</td></tr><tr style='height:20px;'><th id="0R13" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">14</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Mueck_2013_23305158</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10" dir="ltr">Ritonavir</td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Rivaroxaban</td><td class="s10" dir="ltr">Yes</td><td class="s10"></td><td class="s7" dir="ltr">Steady-state ritonavir significantly increased the AUC and Cmax of rivaroxaban.The mean AUC increased by 153% (90% CI 134%, 174%) and the mean Cmax increased by 55% (90% CI 41%, 69%) com-pared with rivaroxaban alone.</td><td class="s6" dir="ltr">Tables 1 and 2; Figure 1</td></tr><tr style='height:20px;'><th id="0R14" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">15</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Mueck_2013_23305158</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 76px; left: -1px;">Clarithromycin</div></td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Rivaroxaban</td><td class="s10" dir="ltr">Yes</td><td class="s10"></td><td class="s7" dir="ltr">Co-administration with clarithromycin significantly increased the mean AUC and Cmax by 54% (90% CI 44%, 64%) and 40% (90% CI 30%, 52%), respectively, in comparison with rivaroxaban alone.</td><td class="s6" dir="ltr">Tables 1 and 2; Figure 1</td></tr><tr style='height:20px;'><th id="0R15" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">16</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Mueck_2013_23305158</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 76px; left: -1px;">Erythromycin</div></td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Rivaroxaban</td><td class="s10" dir="ltr">Yes</td><td class="s10"></td><td class="s7" dir="ltr">With co-administration with erythromycin, the mean AUC and Cmax of rivaroxaban significantly increased (by 34% [90% CI 23%,46%] and 38% [90%CI 21%, 48%], respectively compared with rivaroxaban alone.</td><td class="s6" dir="ltr">Tables 1 and 2; Figure 1</td></tr><tr style='height:20px;'><th id="0R16" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">17</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Mueck_2013_23305158</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10" dir="ltr">Fluconazole</td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Rivaroxaban</td><td class="s10" dir="ltr">Yes</td><td class="s10"></td><td class="s7" dir="ltr">Co-administration with fluconazole significantly increased both the mean AUC and mean Cmax (by 42% [90% CI 29%, 56%]and 28% [90% CI 12%, 47%], respectively) in comparison with rivaroxaban alone.</td><td class="s6" dir="ltr">Tables 1 and 2; Figure 1</td></tr><tr style='height:20px;'><th id="0R17" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">18</div></th><td class="s4" dir="ltr" rowspan="8">7</td><td class="s13" dir="ltr" rowspan="8">http://localhost/dbmiannotator/PMC2764168.html</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Pham_2009_19667285</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 76px; left: -1px;">Tipranavir + Ritonavir</div></td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Atorvastatin</td><td class="s10" dir="ltr">Yes</td><td class="s10"></td><td class="s7" dir="ltr">The geometric mean (GM) ratio was 1.37 (90% confidence interval [CI], 1.15 to 1.62) for the area under the concentration-time curve (AUC) for rosuvastatin with TPV/r at steady state versus alone. The GM ratio was 9.36 (90% CI, 8.02 to 10.94) for the AUC of atorvastatin with TPV/r at steady state versus alone. Tipranavir PK parameters were not affected by single-dose rosuvastatin or atorvastatin.</td><td class="s6" dir="ltr">Fig 1, 2, 3<br> Tables 1, 2, 3</td></tr><tr style='height:20px;'><th id="0R18" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">19</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Pham_2009_19667285</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 76px; left: -1px;">Tipranavir + Ritonavir</div></td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Rosuvastatin</td><td class="s7" dir="ltr">Yes</td><td class="s7" dir="ltr"></td><td class="s7" dir="ltr">The geometric mean (GM) ratio was 1.37 (90% confidence interval [CI], 1.15 to 1.62) for the area under the concentration-time curve (AUC) for rosuvastatin with TPV/r at steady state versus alone. The GM ratio was 9.36 (90% CI, 8.02 to 10.94) for the AUC of atorvastatin with TPV/r at steady state versus alone. Tipranavir PK parameters were not affected by single-dose rosuvastatin or atorvastatin.</td><td class="s6" dir="ltr">Fig 1, 2, 3<br> Tables 1, 2, 3</td></tr><tr style='height:20px;'><th id="0R19" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">20</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Pham_2009_19667285</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">Against</td><td class="s10" dir="ltr">Atorvastatin</td><td class="s10" dir="ltr">interacts_with</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 97px; left: -1px;">Tipranavir + Ritonavir</div></td><td class="s7" dir="ltr">No</td><td class="s7" dir="ltr">A single dose is not sufficient to represent the clinical usage of atorvastatin because it does accumulate at steady state.</td><td class="s7" dir="ltr">The geometric mean (GM) ratio was 1.37 (90% confidence interval [CI], 1.15 to 1.62) for the area under the concentration-time curve (AUC) for rosuvastatin with TPV/r at steady state versus alone. The GM ratio was 9.36 (90% CI, 8.02 to 10.94) for the AUC of atorvastatin with TPV/r at steady state versus alone. Tipranavir PK parameters were not affected by single-dose rosuvastatin or atorvastatin.</td><td class="s6" dir="ltr">Fig 1, 2, 3<br> Tables 1, 2, 3</td></tr><tr style='height:20px;'><th id="0R20" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">21</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Pham_2009_19667285</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">Against</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 76px; left: -1px;">Rosuvastatin</div></td><td class="s10" dir="ltr">interacts_with</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 97px; left: -1px;">Tipranavir + Ritonavir</div></td><td class="s7" dir="ltr">Yes</td><td class="s7" dir="ltr"></td><td class="s7" dir="ltr">The geometric mean (GM) ratio was 1.37 (90% confidence interval [CI], 1.15 to 1.62) for the area under the concentration-time curve (AUC) for rosuvastatin with TPV/r at steady state versus alone. The GM ratio was 9.36 (90% CI, 8.02 to 10.94) for the AUC of atorvastatin with TPV/r at steady state versus alone. Tipranavir PK parameters were not affected by single-dose rosuvastatin or atorvastatin.</td><td class="s6" dir="ltr">Fig 1, 2, 3<br> Tables 1, 2, 3</td></tr><tr style='height:20px;'><th id="0R21" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">22</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Pham_2009_19667285</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 76px; left: -1px;">Tipranavir + Ritonavir</div></td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Rosuvastatin</td><td class="s7" dir="ltr">Yes</td><td class="s7" dir="ltr"></td><td class="s7" dir="ltr">With TPV/r coadministration, the GM AUC for rosuvastatin was<br> 38.6 ng h/ml, a 37% increase compared with that of rosuvastatin<br> alone (P 0.0006) (Fig. 1 and 2).</td><td class="s6" dir="ltr">Table 1<br> Figure 1, 2</td></tr><tr style='height:20px;'><th id="0R22" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">23</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Pham_2009_19667285</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">Against</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 76px; left: -1px;">Rosuvastatin</div></td><td class="s10" dir="ltr">interacts_with</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 97px; left: -1px;">Tipranavir + Ritonavir</div></td><td class="s7" dir="ltr">No</td><td class="s7" dir="ltr">Both rosuvastatin and atorvastatin accumulate during chronic dosing. A single dose study is not sufficient to determine propensity for inhibition</td><td class="s7" dir="ltr">Tipranavir and ritonavir PK parameters were not affected<br> by single-dose rosuvastatin (see Table 3).</td><td class="s6" dir="ltr">Table 3</td></tr><tr style='height:20px;'><th id="0R23" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">24</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Pham_2009_19667285</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 76px; left: -1px;">Tipranavir + Ritonavir</div></td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Atorvastatin</td><td class="s7" dir="ltr">Yes</td><td class="s7" dir="ltr"></td><td class="s7" dir="ltr">TPV/r increased the dose-adjusted atorvastatin AUC0– and Cmax by<br> approximately ninefold (Table 2; Fig. 3 and 4).</td><td class="s6" dir="ltr">Table 2<br> Figure 3, 4</td></tr><tr style='height:20px;'><th id="0R24" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">25</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Pham_2009_19667285</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">Against</td><td class="s10" dir="ltr">Atorvastatin</td><td class="s10" dir="ltr">interacts_with</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 97px; left: -1px;">Tipranavir + Ritonavir</div></td><td class="s7" dir="ltr">No</td><td class="s7" dir="ltr">Both rosuvastatin and atorvastatin accumulate during chronic dosing. A single dose study is not sufficient to determine propensity for inhibition</td><td class="s7" dir="ltr">Single-dose atorvastatin did not affect the steady-state PKs<br> of tipranavir (Table 3).</td><td class="s6" dir="ltr">Table 3</td></tr><tr style='height:20px;'><th id="0R25" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">26</div></th><td class="s14" dir="ltr" rowspan="2">8</td><td class="s15" dir="ltr" rowspan="2"><a target="_blank" href="http://localhost/dbmiannotator/PMC2686069.html">http://localhost/dbmiannotator/PMC2686069.html</a></td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Walker_2009_03065251</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">Against</td><td class="s10" dir="ltr">Ambrisentan</td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Warfarin</td><td class="s7" dir="ltr">Yes</td><td class="s7" dir="ltr"></td><td class="s7" dir="ltr">The concentration–time proﬁles of both warfarin enantiomers were virtually superimposable in the presence (day13 ) or absence (day1 of ambrisentan. Following multiple doses of ambrisentan, the observed mean AUC0–last values for R- and S-warfarin increased by 4.7% (GMR 104.7; 90% CI 101.7, 107.7) and 1.6% (101.6; 90% CI 98.4, 105.0), respectively, and mean Cmax values decreased for both enantiomers by 8.4% (91.6;90% CI 86.2,97.4) and 10.1% (93.0; 90% CI 90.8, 95.3), respectively (Table1</td><td class="s6" dir="ltr">Fig 2, Fig 4, Table 1</td></tr><tr style='height:20px;'><th id="0R26" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">27</div></th><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Walker_2009_03065251</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">Against</td><td class="s10" dir="ltr">Warfarin</td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Ambrisentan</td><td class="s7" dir="ltr">No</td><td class="s7" dir="ltr">Not sufficient to determine whether warfarin alters ambrisentan since only a single dose of warfarin was administered</td><td class="s7" dir="ltr">In the presence of warfarin, steady-state AUC0–t (where t is the length of the24-hdosinginterval) decreasedby12.2% (87.8;90%CI 83.9, 91.8).</td><td class="s6" dir="ltr">Fig 2, Fig 4, Table 3</td></tr><tr style='height:20px;'><th id="0R27" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">28</div></th><td class="s14" dir="ltr">9</td><td class="s15" dir="ltr"><a target="_blank" href="http://localhost/dbmiannotator/PMC3703233.html">http://localhost/dbmiannotator/PMC3703233.html</a></td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 131px; left: -1px;">Delavenne_2013_03065251.html.pdf</div></td><td class="s10" dir="ltr">clinical study</td><td class="s10" dir="ltr">For</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 76px; left: -1px;">Clarithromycin</div></td><td class="s10" dir="ltr">interacts_with</td><td class="s10" dir="ltr">Dabigatran</td><td class="s7" dir="ltr">Needs to be evaluated</td><td class="s7" dir="ltr"></td><td class="s7" dir="ltr">On AUC, an increase of 49.1% was observed from 1220.5mgl -1 h (586.5–2227.2) without clarithromycin to 1820.4mgl -1 h (521.0–5000.2) with clarithromycin.</td><td class="s6" dir="ltr">Figure 3</td></tr><tr style='height:20px;'><th id="0R28" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px;">29</div></th><td class="s14" dir="ltr">10</td><td class="s15" dir="ltr"><a target="_blank" href="http://localhost/dbmiannotator/PMC3091944.html">http://localhost/dbmiannotator/PMC3091944.html</a></td><td class="s6" dir="ltr">Frymoyer_2010_00099236.pdf</td><td class="s11"></td><td class="s10" dir="ltr">For</td><td class="s10" dir="ltr">Warfarin</td><td class="s10 softmerge" dir="ltr"><div class="softmerge-inner" style="width: 97px; left: -1px;">is_not_substrate_of</div></td><td class="s10" dir="ltr">OATP1B1</td><td class="s7" dir="ltr">Yes</td><td class="s7" dir="ltr"></td><td class="s7" dir="ltr">coadministration of the potent OATP inhibitor rifampin, given as a single intravenous dose, had no effect on the AUC0–12 h and Cmax values of S- and R-warfarin or on S-warfarin’s hydroxyl metabolite. Accordingly,<br> OATP uptake transport is likely not clinically significant for the<br> disposition of warfarin and will provide no further insight into mechanisms of warfarin drug–drug interactions or geneticvariation important in warfarin dose selection.</td><td class="s6" dir="ltr">Figure 2</td></tr></tbody></table></div>
<script type='text/javascript'>
function posObj(sheet, id, row, col, x, y) {
  var rtl = false;
  var sheetElement = document.getElementById(sheet);
  if (!sheetElement) {
    sheetElement = document.getElementById(sheet + '-grid-container');
  }
  if (sheetElement) {
    rtl = sheetElement.getAttribute('dir') == 'rtl';
  }
  var r = document.getElementById(sheet+'R'+row);
  var c = document.getElementById(sheet+'C'+col);
  if (r && c) {
    var objElement = document.getElementById(id);
    var s = objElement.style;
    var t = y;
    while (r && r != sheetElement) {
      t += r.offsetTop;
      r = r.offsetParent;
    }
    var offsetX = x;
    while (c && c != sheetElement) {
      offsetX += c.offsetLeft;
      c = c.offsetParent;
    }
    if (rtl) {
      offsetX -= objElement.offsetWidth;
    }
    s.left = offsetX + 'px';
    s.top = t + 'px';
    s.display = 'block';
    s.border = '1px solid #000000';
  }
};
function posObjs() {
};
posObjs();</script>
